What is your assessment of the performance of the two heavyweight project teams described in the Eli Lilly case? What factors contributed most to these performance results? In the pharmaceutical context, how far back in the development process should heavyweight teams be deployed (e.g., just for Phase III, Phase II-B, Phase-in-A, Phase I)?Why? Here you will beexamining the impact of this team structure on the Zyprexa and Evistaprojects (i.e., what the benefits have been of the heavyweight approach) and exploring what is it about this team structure that provided those benefits.